The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pyadushkina E.A.

National Center for Health Technology Assessment

Ignatieva V.I.

National Medical Research Center for Therapy and Preventive Medicine;
I.M. Sechenov First Moscow State Medical University (Sechenov University);
Russian Medical Academy of Continuing Professional Education

Yagnenkova E.E.

National Center for Health Technology Assessment

Derkach E.V.

National Center for Health Technology Assessment

Cost-effectiveness analysis of anifrolumab therapy in patients with systemic lupus erythematosus in the Russian Federation

Authors:

Pyadushkina E.A., Ignatieva V.I., Yagnenkova E.E., Derkach E.V.

More about the authors

Journal: Medical Technologies. Assessment and Choice. 2023;45(4): 33‑41

DOI: 10.17116/medtech20234504133

Read: 2351 times

Download PDF (RU)
Contact the author
Table of contents

COST-EFFECTIVENESS ANALYSIS OF ANIFROLUMAB THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE RUSSIAN FEDERATION
COST-EFFECTIVENESS ANALYSIS OF ANIFROLUMAB THERAPY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS IN THE RUSSIAN FEDERATION

To cite this article:

Pyadushkina EA, Ignatieva VI, Yagnenkova EE, Derkach EV. Cost-effectiveness analysis of anifrolumab therapy in patients with systemic lupus erythematosus in the Russian Federation. Medical Technologies. Assessment and Choice. 2023;45(4):33‑41. (In Russ.)
https://doi.org/10.17116/medtech20234504133

 
Подписка 2026 Медицинские технологии. Оценка и выбор (Medical Technologies. Assessment and Choice)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Is arti­ficial inte­lligence nece­ssary for healthcare system?. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):40-48
Cost-effectiveness analysis of deno­sumab therapy in adults with solid tumors and bone meta­stases (in Russian healthcare). Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):74-89
Economic issues of medi­cal care for hype­rparathyroidism. Part 1. Primary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):51-61
Cost-effectiveness analysis of bariatric surgery in obese patients. Medi­cal Technologies. Asse­ssment and Choice. 2025;(1):62-75
Pharmacoeconomic analysis of the neta­kimab use for the treatment of psoriasis vulgaris in the health care settings of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):99-105
Economics of hype­rparathyroidism. Part 2 — seco­ndary hype­rparathyroidism. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):74-82
Cost-effectiveness analysis of triptorelin therapy for patients with prostate cancer in state healthcare system of the Russian Fede­ration. Medi­cal Technologies. Asse­ssment and Choice. 2025;(3):83-92
Central nervous system invo­lvement in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):124-129
Masks of autoimmune diseases: a multidisciplinary approach to the problem. Journal of Respiratory Medi­cine. 2025;(1):58-64
Abstract:

OBJECTIVE

Cost-effectiveness analysis of anifrolumab therapy in adults with moderate-to-severe systemic lupus erythematosus in the Russian Federation.

MATERIAL AND METHODS

We performed cost-effectiveness analysis to assess incremental cost-effectiveness ratio (ICER) for anifrolumab compared to belimumab in addition to standard therapy. Considering the results of indirect comparison, we established the criteria of effectiveness. Analysis of costs was based on government procurement of drugs and registered prices of drugs from the list of vital and essential drugs. Dosages of drugs were determined in accordance with instructions and clinical recommendations. Finally, we performed a sensitivity analysis varying the input parameters.

RESULTS

Anifrolumab has a significant advantage in effectiveness compared to belimumab. The odds ratio for response to therapy (SRI-4 criterion) is 2.61 (95% CI 1.22—5.58). The cost of 52-week anifrolumab therapy in addition to standard therapy is 1.3 million rubles per a patient, the cost of belimumab therapy — 0.62 million rubles. Additional costs per a patient with SRI-4 response (ICER) amounted to 3.49 million rubles when using anifrolumab compared to belimumab. This value is lower than ICER for belimumab in addition to standard therapy compared to standard therapy (5.08 million rubles). Sensitivity analysis demonstrates robustness of results to varyability of input values.

CONCLUSION

Clinical effectiveness of anifrolumab therapy is significantly higher compared to belimumab according to SRI-4 criterion, but this therapy requires greater costs. Incremental cost for achieving SRI-4 response in 1 additional patient is 31.15% lower for anifrolumab compared to belimumab than for belimumab compared to standard therapy. Therefore, anifrolumab therapy is economically feasible in patients with moderate-to-severe systemic lupus erythematosus.

Keywords:

systemic lupus erythematosus
anifrolumab
belimumab
cost-effectiveness analysis

Authors:

Pyadushkina E.A.

National Center for Health Technology Assessment

Ignatieva V.I.

National Medical Research Center for Therapy and Preventive Medicine;
I.M. Sechenov First Moscow State Medical University (Sechenov University);
Russian Medical Academy of Continuing Professional Education

Yagnenkova E.E.

National Center for Health Technology Assessment

Derkach E.V.

National Center for Health Technology Assessment

Received:

07.09.2023

Accepted:

19.09.2023

Close metadata

References:

  1. Rossijskie klinicheskie rekomendatsii. Revmatologiya. Pod red. Nasonova E.L. M.: GEOTAR-Media; 2017. (In Russ.).
  2. Aseeva EA, Soloviev SK, Popkova TV, Nikishina NYu, Mesnyankina AA. Management of patients with systemic lupus erythematosus in real clinical practice. Rheumatology Science and Practice. 2019;57(2):191-196. (In Russ.). https://doi.org/10.14412/1995-4484-2019-191-196
  3. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nature Reviews Rheumatology. 2016;12(10):605-20.  https://doi.org/10.1038/nrrheum.2016.137
  4. Nasonov E, Soloviev S, Davidson JE, Lila A, Ivanova R, Togizbayev G, et al. The prevalence and incidence of Systemic Lupus Erythematosus (SLE) in selected cities from three Commonwealth of Independent States countries (the Russian Federation, Ukraine and Kazakhstan). Lupus. 2013;23(2):213-219.  https://doi.org/10.1177/0961203313512881
  5. Cervera R, Khamashta M, Hughes G. The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe. Lupus. 2009;8(10):869-874.  https://doi.org/10.1177/0961203309106831
  6. Ismagilova RR, Zamanova ES, Maksudova AN. Survival rates in patients with systemic lupus erythematosus: regional registry data. Rheumatology Science and Practice. 2020;58(2):154-159. (In Russ.). https://doi.org/10.14412/1995-4484-2020-154-159
  7. Federal’nye klinicheskie rekomendatsii po diagnostike i lecheniyu sistemnoj krasnoj volchanki. Assotsiatsiyarevmatologov Rossii. Accessed October 08, 2023. (In Russ.). https://rheumatolog.ru/experts/klinicheskie-rekomendacii/
  8. Rekomendatsii lecheniyu sistemnoj krasnoj volchanki. Accessed October 08, 2023. (In Russ.). https://rheumatolog.ru/upload/iblock/2e3/3tw49hdcelhlscvvwsom7q2f3io55c61/natrec09.pdf
  9. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019;78(6):736.  https://doi.org/10.1136/annrheumdis-2019-215089
  10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheumatism. 1992;35(6):630-640.  https://doi.org/10.1002/art.1780350606
  11. Ohmura K. Which is the best SLE activity index for clinical trials? Modern Rheumatology. 2020;31(1):1-23.  https://doi.org/10.1080/14397595.2020.1775928
  12. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Quarterly Journal of Medicine. 1993;86(7):447-458. 
  13. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology. 2005;44(7):902-906.  https://doi.org/10.1093/rheumatology/keh624
  14. Yee C-S, Farewell V, Isenberg DA, Griffiths B, Teh L-S, Bruce IN, et al. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity. Rheumatology. 2009;48(6):691-695.  https://doi.org/10.1093/rheumatology/kep064
  15. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Care and Research. 2009;61(9):1143-1151. https://doi.org/10.1002/art.24698
  16. Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, et al. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research. 2022;11(10):765-777.  https://doi.org/10.2217/cer-2022-0040
  17. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. Accessed October 08, 2023. (In Russ.). https://www.nicedsu.org.uk/wp-content/uploads/2017/05/Population-adjustment-TSDFINAL.pdf
  18. Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ, et al. Methods for Population-Adjusted Indirect Comparisons in Health Technology Appraisal. Medical Decision Making. 2018;38(2):200-211.  https://doi.org/10.1177/0272989X17725740
  19. Morand EF, Furie R, Tanaka Yo, Bruce IN, Askanase AD, Richez C, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine. 2020;382(3):211-221.  https://doi.org/10.1056/NEJMoa1912196
  20. Furie RA, Morand EF, Bruce IN, Manzi S, Kalunian KC, Vital EM, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology. 2019;1(4):e208-e219. https://doi.org/10.1016/S2665-9913(19)30076-1
  21. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheumatism. 2011;63(12):3918-3930. https://doi.org/10.1002/art.30613
  22. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.  https://doi.org/10.1016/S0140-6736(10)61354-2
  23. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Annals of the Rheumatic Diseases. 2012;71(11):1833-1838. https://doi.org/10.1136/annrheumdis-2011-200831
  24. Epidemiologicheskij slovar’. Pod red. Dzhona M. Lasta. M.: Otkrytyj Institut Zdorov’ya; 2009. (In Russ.).
  25. JavaStat-2-way Contingency Table Analysis. Accessed October 08, 2023. (In Russ.). https://statpages.info/ctab2x2.html
  26. Gosudarstvennyj reestr predel’nyh otpusknyh cen proizvoditelej na lekarstvennye preparaty, vklyuchennye v perechen’ zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov. Accessed August 17, 2023. (In Russ.). https://grls.rosminzdrav.ru/pricelims.aspx
  27. Oficial’nyj sajt edinoj informacionnoj sistemy v sfere zakupok. Accessed August 17, 2023. (In Russ.). https://zakupki.gov.ru/epz/main/public/home.html
  28. NICE. STA Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus. Manufacturers submission GlaxoSmithKline. Accessed October 13, 2021. https://www.nice.org.uk/guidance/ta397/documents/systemic-lupus-erythematosus-activebelimumab-manufacturers-submission-glaxosmithkline2
  29. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Benlista. Accessed October 08, 2023. (In Russ.). https://grls.rosminzdrav.ru/InstrImg/2021/09/28/1473756/79fe91aad7de-4d1a-ade4-0efc90e1e689.pdf
  30. Instrukciya po medicinskomu primeneniyu lekarstvennogo preparata Safnelo. Accessed October 08, 2023. (In Russ.). https://grls.rosminzdrav.ru/InstrImg/2023/03/17/1491908/4d650d01-6ce4-412f-9ef4-e6b1de9a34a2.pdf
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.